24th Porto Cancer Meeting 2017
Liquid biopsy: bringing precision medicine closer to oncology
Candiolo Cancer Institute IRCCS, University of Torino
Associate Professor at University of Torino, Dept. of Oncology and Director of the Laboratory of Molecular Oncology at the Candiolo Cancer Institute-IRCCS, Candiolo (Torino, Italy).
Prof. Bardelli received a PhD in Biochemistry and Molecular Biology at UCL (London, UK) in 1996. As a post doc at the Howard Hughes Medical Institute at the Johns Hopkins University (Baltimore, USA), in the group led by Bert Vogelstein, he has developed the first comprehensive mutational profile of kinases in CRCs.
As an independent investigator Prof. Bardelli has then translated these findings into clinical practice by discovering that K-RAS (B-RAF) mutations impart resistance to EGFR-targeted agents. These findings were later confirmed by independent laboratories with such compelling evidence that they were rapidly translated into clinically applicable predictive biomarkers (genomic signatures) currently used to select patients for anti EGFR therapy.
Recently, Prof. Bardelli’s work has defined mechanisms of acquired resistance to anti EGFR therapies in colorectal cancer patients thus providing insights into new therapies aimed at overcoming resistance. These studies involve an innovative methodology – named liquid biopsy – which allows the use of circulating tumor DNA to monitor patient’s response using a blood draw.
In 2014 he has been listed in the Thomson Reuters List of Highly Cited Researchers (http://highlycited.com/). His H factor is 62.